Intralipid to enhance the efficacy of chemotherapy treatment

Based on a new study from Carnegie Mellon University and Taiwan’s National Health Research Institutes, using chemotherapy nanodrugs with a nutritional supplement can help reduce the deadly effects. In addition, it will also help in reducing the amount of expensive drugs which are necessary in the treatment of cancer.

Experts also underline that pretreatment with supplement enhances the production of tumor-killing macrophages, thus making it a promising complement as well as supplement to present chemotherapies.

The latest study shows that administering anti-cancer drugs with FDA-approved nutrition source-Intralipid, is ready to be introduced in the early stage clinical trials and will be studied for the use with other nanodrugs.

“The combination of anti-cancer nanodrugs with Intralipid enhances the inhibition of tumor growth and may serve as a novel strategy to improve therapeutic efficacy in treating cancers in clinical practice,” explained Chien Ho.

Nanodrugs like paclitaxel are regarded as effective in killing cancer cells, which is less than one percent of the expensive drugs which reach tumor cells. Experts reveal the rest is to be absorbed by other cells, particularly those on kidneys, spleen and liver. This further leads to toxic side effects which are significantly represent chemotherapy.

Current study explores the impact on human cells in vitro by combining Abraxane, type of paclitaxel used to treat a number of cancers, with Intralipid. Results concluded that the combination protected monocytic white blood cells from damage without impacting the drug’s efficacy in killing breast, lung or pancreatic cancer cells.

Furthermore, Intralipid also impacted macrophages, and large white blood cells that have a significant role in the immune response.

“By decreasing the amount of Abraxane needed in treating cancers, we can protect the organs from some of the chemical damage done by the drug,” explained Ho.

“This new nanodrug delivery method is a general one and can be applied to other approved and in-development nanodrugs without any modifications to the drugs or their carriers,” added Ho. “This drug delivery method can reduce the amount of drugs needed for treatment, improving the quality of life for patients and reducing the cost of treatment with these expensive drugs.”